Metformin reduces odds of developing Acute Macular Degeneration among diabetes patients

Written By : Dr.Niharika Harsha B |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-12-22T20:00:04+05:30 | Updated On 22 Dec 2022 8:00 PM IST

A recent meta-analysis found that diabetic patients using Metformin have decreased odds of developing age-related macular degeneration (AMD). The study results were published in the journal Investigative Ophthalmology & Visual Science.

Diabetes is commonly treated with Metformin, a biguanide derivative. It exhibits antioxidative, anti-inflammatory, and antiangiogenic activity within the ocular tissue and is hence implicated in the treatment of age-related macular degeneration (AMD). Due to the uncertainty in the past literature, researchers from the U.S.A conducted a systematic review and meta-analysis to establish the conducive effect of metformin usage on AMD.

Also Read: RenalGuard ineffective in preventing high-risk contrast-induced nephropathy

Databases like The Ovid MEDLINE/Embase, Cochrane Library, and Web of Science were systematically searched from inception through August 3, 2022. Studies reporting the association between metformin use and odds of AMD were enrolled. Adjusted odds ratios (ORs) of AMD were extracted and random-effects model meta-analysis was used for pooling. Subgroup analyses were conducted based on AMD subtypes, ethnicity, study design, sex, and confirmation of AMD diagnosis.

Findings from the study:

A total of 9 observational studies with 14,46,284 participants were included in the analysis.
There was a significant reduction in the odds of AMD with metformin use as shown in the meta-analysis (pooled ORs = 0.81, 95% confidence interval [CI] = 0.70–0.93).
Metformin use was not significantly associated with dry or wet AMD as per subgroup analysis.
Significantly lower odds of AMD were especially seen in the Black (pooled ORs = 0.61, 95% CI = 0.58–0.64) and Hispanic populations (pooled ORs = 0.85, 95% CI = 0.81–0.89).

Also, Read Ranitidine Use in Drug-Induced Gastritis-Here's What Experts Say !!!

Thus, the present study was the first of its kind to confirm that oral metformin use was associated with 0.81-fold decreased odds of AMD. But further prospective trials that explore the therapeutic effect of metformin on diabetic patients are needed.

Further reading: Liang KH, Chen CH, Tsai HR, Chang CY, Chen TL, Hsu WC. Association Between Oral Metformin Use and the Development of Age-Related Macular Degeneration in Diabetic Patients: A Systematic Review and Meta-Analysis. Invest Ophthalmol Vis Sci. 2022;63(13):10. doi:10.1167/iovs.63.13.10

DiabetesDiabetes careMetforminage related macular degeneration

Source : Investigative Ophthalmology and Visual Science

Dr.Niharika Harsha B

BDS, MDS

Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751